Atonomics achieves significant milestone related to performance data for Troponin I assay triggering scheduled payments from Beckman Coulter

Atonomics A/S announced today that it has achieved an important milestone related to a defined set of performance criteria for a Troponin I assay on the new Atolyzer® system.

Since entering an equity investment agreement with Beckman Coulter in May of last year to advance the Atolyzer® within cardiac testing, the company has worked diligently to deliver relevant Troponin I performance data.

“We are pleased to achieve this milestone,” said Thomas Warthoe, Atonomics’ CEO. “Troponin I is one of the most difficult assays to transfer to a near-patient system and still deliver data that are comparable to what the physicians get from the central laboratory; we believe the Atolyzer® has the potential to allow physicians in the future to continue to safely implement data from a near patient system.”

“We expect that this recent and significant achievement will generate appropriate interest from Industry in order to reach the full potential of the Atolyzer® platform”, said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with Inventages Venture Capital

Atonomics’ majority shareholders are Inventages Venture Capital, Sunstone Capital, NeuroSearch A/S, and Beckman Coulter.

About Atonomics Atonomics is an emerging technology company based in Copenhagen, Denmark, that designs and manufactures the innovative Atolyzer® system for near-patient testing in hospitals, clinics, physician offices and patient monitoring. Atonomics is pursuing a strategy to partner with leading players in the industry to bring a new dimension of quality to the point-of-care market. The Atolyzer® system is a platform for immuno-diagnostic and molecular diagnostic testing. The Atolyzer® is designed for simplicity and ease of use while preserving performance and safety. The stand-alone device is operated with a single touch by any health worker and can be positioned in any location throughout the hospital, clinic or office where large systems cannot operate, representing true near-patient testing.

Trace® is now ready for ordering

€ 2495 Trace® device                
€ 15 each Lipids capsule  
€ 120 for 10 Lipids capsules

We will on a continuous basis release more and more important biomarker capsules.

Trace is available now for you to get started with this important biomarker monitoring device.


From 2018 we will have semi-automated important production procedures and thus can sell at a lower price. 

We allow you to pre-order now for below pricing with delivery time before end of 2018.

€ 695 Trace® device
€ 15 each Lipids capsule or
€ 120 for 10 Lipids capsules

Orders will be shipped on a first incoming order basis.

Continue ordering